Carlsmed (CARL) delivered the quarter growth investors wanted to see. Third-quarter revenue rose 64.9% year over year to $21.55 million, beating the $19.58 million consensus by 10.1%. The adjusted loss of $0.34 per share topped the -$0.42 consensus by 19.0% and improved 15.0% from a year ago. Management also raised full-year 2026 revenue guidance to $78 million to $80 million, up from $74 million to $78 million. The central takeaway is that top-line growth is accelerating, not fading. Revenue growth of 65% followed 57% in the second quarter and 58% in the first, which is unusual for a young medtech company that is lapping increasingly difficult comparisons.
The quality of the earnings beat deserves more scrutiny than the revenue beat. On a GAAP basis, the net loss widened to $12.2 million, or $0.45 per share, from $8.5 million, or $0.40 per share, a year earlier. Operating expenses climbed 55% to $29.4 million, and general and administrative spending roughly doubled to $10.0 million. Part of that increase came from $2.8 million of executive transition costs and the expected resolution of undisclosed legal matters, which the adjusted figures exclude. Stock-based compensation also jumped to $2.5 million from $0.7 million. The adjusted figures still tell a constructive story. Adjusted EBITDA improved to -$7.3 million from -$8.6 million in the second quarter and -$8.2 million a year ago. Management called this the company's first quarter of positive operating leverage and an "inflection point." That is a fair description of the adjusted trend, but the GAAP picture is noisier than the headline surprise implies.
Beneath the numbers, demand indicators were strong:
- **Procedure volume:** grew 76% in newly disclosed figures, outpacing revenue.
- **Surgeon base:** expanded more than 60% for a fourth straight quarter.
- **Cervical mix:** rose to 12% of revenue from roughly 10% in the second quarter, ahead of expectations.
- **Gross margin:** reached 77.3%, up from 76.8% sequentially and 75.9% a year ago, and management reaffirmed its high-70s outlook.
The softer detail is that margin expansion is slowing. The year-over-year improvement was 140 basis points, compared with 340 basis points in the second quarter. That suggests the easy gross-margin gains are largely behind the company, and future leverage will have to come from operating expenses.
The forward catalyst list is unusually dense:
- New lumbar MS-DRGs under the fiscal 2027 CMS inpatient rule took effect October 1, raising reimbursement for inpatient aprevo procedures. Management cited an uptick in new hospital contracts exiting the third quarter.
- The aprevo bilateral posterior system launched on schedule in October, addressing an estimated 30,000 U.S. lumbar fusions annually.
- CORA cervical plating is expected to launch fully within weeks.
- New two-year data on low-bone-density patients showed a roughly 6% reoperation rate, though that figure comes from an unadjusted cross-study comparison.
That is the central tension: with this many launches and a reimbursement tailwind arriving at once, the guidance looks conservative. The nine-month revenue total of $56.6 million implies fourth-quarter revenue of roughly $21.4 million to $23.4 million. At the low end, that is below the third quarter's result, and analysts flagged the step-up as lighter than prior years' fourth-quarter cadence. Either management is sandbagging after three consecutive raises, or launch ramps and hospital contracting will take longer to show up in revenue.
Bears have legitimate ammunition beyond the guidance:
- The CFO changed mid-year.
- The legal matters remain undisclosed.
- Competitors are expected to enter the custom-implant market in 2027, which could challenge Carlsmed's differentiation just as its new products scale.
- Cash fell to $80.3 million from $89.3 million after $9.0 million of quarterly burn, up from $7.4 million in operating cash use in the second quarter.
The balance sheet is not an immediate concern. Even so, investors will want rising revenue to narrow burn rather than widen it.
Investor sentiment improved heading into the report but remained slightly negative, moving from -0.18 to -0.05. The stock has already been rewarding the growth story. Shares closed at $16.05 before the release, up 15.5% from the $13.90 open after the August report and nearly 29% above the 200-day moving average of $12.47. The stock set a 52-week high of $17.23 on August 21 and entered earnings about 7% below that level, in the upper portion of its $13.30 to $17.23 inter-earnings range. The Earnings Whispers trend readings are mostly positive, with sequential growth, momentum, and AVWAP all pointing upward. The market setup is therefore less about whether growth is real and more about whether the fourth-quarter guide is too cautious.
The bottom line is that Carlsmed's revenue engine is accelerating, its guidance keeps moving higher, and adjusted profitability has started to turn. Those are the developments that matter most for a high-growth medtech story. Offsetting them are a widening GAAP loss, one-time costs tied to leadership turnover and legal issues, slowing gross-margin gains, rising cash burn, and a fourth-quarter outlook that looks modest. With the stock trading well above its long-term average and sentiment still slightly negative, the coming quarters will test whether the DRG tailwind and new launches can turn conservative guidance into another round of upside.